Real World Outcomes with Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma (RRMM)

被引：1
|
作者：
Gill, Sarvarinder Kaur [1 ]
Fleming, Erika [2 ]
Gebre, Helen [1 ]
Bangolo, Ayrton, I [3 ]
Siegel, David S. [4 ,5 ]
Vesole, David H. [6 ]
Biran, Noa [6 ]
Parmar, Harsh [6 ]
Phull, Pooja [6 ]
机构：
[1] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Hackensack Meridian Sch Med, Nutley, NJ USA
[3] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Edgewater, NJ USA
[4] Hackensack Meridian Hlth, John Theurer Canc Ctr, Div Multiple Myeloma, Hackensack, NJ USA
[5] Ctr Discovery & Innovat, Hackensack, NJ USA
[6] Hackensack Univ Med Ctr, Div Multiple Myeloma, John Theurer Canc Ctr, Hackensack, NJ USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-210350
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7047 / 7048
页数：2
相关论文
共 50 条
  • [31] Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Polepally, Akshanth R.
    Biesdorf, Carla
    Uddin, Muhammad Erfan
    Boehm, Nils
    Ross, Jeremy A.
    Kumar, Shaji Kunnathu
    Voorhees, Peter M.
    D'Souza, Anita
    Weisel, Katja
    Bueno, Orlando
    Talati, Chetasi
    Menon, Rajeev M.
    BLOOD, 2023, 142
  • [32] A research center's experience of T-cell-redirecting therapies in triple-class refractory multiple myeloma
    Puertas, Borja
    Fernandez-Sanchez, Adolfo
    Alejo, Elena
    Rey-Bua, Beatriz
    Martin-Lopez, Ana A.
    Perez-Lopez, Estefania
    Lopez-Parra, Miriam
    Lopez-Corral, Lucia
    Gutierrez-Gutierrez, Norma C.
    Garcia-Sanz, Ramon
    Puig, Noemi
    Gonzalez-Calle, Veronica
    Mateos, Maria-Victoria
    BLOOD ADVANCES, 2024, 8 (13) : 3478 - 3487
  • [33] Real-World Experience With Talquetamab Clinical Management in Relapsed Refractory Multiple Myeloma (RRMM): A Qualitative Study of US Healthcare Providers
    Schinke, Carolina
    Dhakal, Binod
    Mazzoni, Sandra
    Shenoy, Samantha
    Scott, Sara
    Richards, Tiffany
    Le, Hoa
    DeBrosse, Amalia
    Okorozo, Peter
    McDowell, Rachel
    Patel, Saurabh
    Bunn, Jonathan
    Hawks, Kelly
    Zhang, Xinke
    Rodriguez-Valdes, Cesar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S265 - S266
  • [34] First Results From the RedirecTT-1 Study With Teclistamab (Tec) plus Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    Cohen, Yael
    Morillo, Daniel
    Gatt, Moshe
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Oriol, Albert
    Ocio, Enrique
    Yoon, Sung-Soo
    Mateos, Maria-Victoria
    Chu, Michael
    Rodriguez-Otero, Paula
    Chu, Michael
    Rodriguez-Otero, Paula
    Avivi, Irit
    Guo, Yue
    Krevvata, Maria
    Peterson, Michelle
    Beelen, Melissa
    Vanak, Jill
    Banerjee, Arnob
    Magen, Hila
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S478 - S479
  • [35] Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1+1 greater than 2?
    Li, Chenggong
    Mei, Heng
    LANCET HAEMATOLOGY, 2024, 11 (10): : e712 - e713
  • [36] BCMA after GPRC5D: Efficacy of BCMA-Directed Therapy on Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Progressing After GPRC5D-Directed Therapy
    Joiner, Laura
    Costa, Luciano
    Giri, Smith
    Ravi, Gayathri
    Godby, Kelly
    Hagedorn, Caitlin
    Bal, Susan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S61 - S62
  • [37] First results from the RedirecTT-1 study with teclistamab (tec) plus talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Cohen, Yael C.
    Morillo, Daniel
    Gatt, Moshe E.
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Oriol, Albert
    Ocio, Enrique M.
    Yoon, Sung-Soo
    Mateos, Maria-Victoria
    Chu, Michael
    Rodriguez-Otero, Paula
    Avivi, Irit
    Guo, Yue
    Krevvata, Maria
    Peterson, Michelle R.
    Beelen, Melissa Jo
    Vanak, Jill
    Banerjee, Arnob
    Magen, Hila
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] POPULATION PHARM ACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) x CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Polepally, A.
    Badillo, J.
    Rinas, M.
    Ahsan, A.
    Bueno, O.
    Talati, C.
    Menon, R.
    Engelhardt, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S69 - S69
  • [39] Updated Results of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study
    Jakubowiak, Andrzej J.
    Anguille, Sebastien
    Karlin, Lionel
    Chari, Ajai
    Schinke, Carolina
    Rasche, Leo
    San-Miguel, Jesus
    Campagna, Michela
    Hilder, Brandi W.
    Masterson, Tara J.
    Qin, Xiang
    Renaud, Thomas
    Tolbert, Jaszianne
    Vishwamitra, Deeksha
    Skerget, Sheri
    Moreau, Philippe
    BLOOD, 2023, 142
  • [40] First results from the RedirecTT-1 study with teclistamab (tec) plus talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Magen, Hila
    Morillo, Daniel
    Gatt, Moshe
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Oriol, Albert
    Ocio, Enrique
    Yoon, Sung-Soo
    Mateos, Maria-Victoria
    Chu, Michael
    Rodriguez-Otero, Paula
    Avivi, Irit
    Guo, Yue
    Krevvata, Maria
    Peterson, Michelle
    Beelen, Melissa
    Vanak, Jill
    Banerjee, Arnob
    Cohen, Yael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S49 - S50
12345